改善肝性脑病患者医疗质量的目标:来自多中心队列的数据
BACKGROUND: Hepatic encephalopathy (HE) can adversely affect outcomes in both in-patients and out-patients with cirrhosis.…
要点
- 药物是最常见诱因(32%),其中乳果糖过量/不足使用占21%。
- 23%患者达到3/4级HE,其中16%发生HE相关吸入性肺炎。
- 90天HE相关再入院率:无治疗9%、利福昔明单药9%、乳果糖单药18%、双药21%(P<0.001)。
核心结论
- 在大量住院肝硬化患者中识别出若干改善HE管理的目标。
- 有必要采取干预措施以减少药物诱发性HE、预防吸入性肺炎并优化HE药物。
研究设计与样本
- 多中心队列研究,分析北美终末期肝病联盟(NACSELD)住院患者队列。
主要发现
- 入院时HE及住院期间HE发生率在乳果糖单药或双药治疗者中最高,与无治疗或利福昔明单药者相比(P < 0.001)。
- 药物是最常见诱因(32%),包括乳果糖过量/不足使用21%、苯二氮䓬类5%、阿片类4%、利福昔明不足使用1%、催眠药1%。
- 药物相关诱因患者预后优于其他诱因患者。
- 23%(n = 217)达到3/4级HE,其中16%发生HE相关吸入性肺炎。
临床怎么用
- 作者认为有必要采取干预措施以减少药物诱发性HE、预防吸入性肺炎并优化HE药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatic encephalopathy (HE) can adversely affect outcomes in both in-patients and out-patients with cirrhosis. AIM: To define targets for improving quality of care in HE management in the multi-centre North American Consortium for End-Stage Liver Disease (NACSELD) cohort. METHOD: NACSELD in-patient cohort was analysed for (a) medication-associated precipitants, (b) aspiration pneumonia development, (c) HE medication changes, and (d) 90-day HE recurrence/readmissions. Comparisons were made between patients on no-therapy, lactulose only, rifaximin only or both. Ninety-day HE-readmission analysis was adjusted for MELD score. RESULTS: Two thousand eight hundred and ten patients (1102 no-therapy, 659 lactulose, 154 rifaximin, 859 both) were included. HE on admission, and HE rates during hospitalisation were highest in those on lactulose only or dual therapy compared to no-therapy or rifaximin only (P < 0.001). Medications were the most prevalent precipitants (32%; 21% lactulose over/underuse, 5% benzodiazepines, 4% opioids, 1% rifaximin underuse, 1% hypnotics). Patients with medication-associated precipitants had a better prognosis compared to other precipitants. A total of 23% (n = 217) reached grade 3/4 HE, of which 16% developed HE-related aspiration pneumonia. Two thousand four hundred and twenty patients were discharged alive without liver transplant (790 no-therapy, 639 lactulose, 136 rifaximin, 855 both); 12.5% (n = 99) of no-therapy patients did not receive a discharge HE therapy renewal. Ninety-day HE-related readmissions were seen in 16% of patients (9% no-therapy, 9% rifaximin only, lactulose only 18%, dual 21%, <0.001), which persisted despite MELD adjustment (P = 0.009). CONCLUSION: Several targets to improve HE management were identified in a large cohort of hospitalised cirrhotic patients. Interventions to decrease medication-precipitated HE, prevention of aspiration pneumonia, and optimisation of HE medications are warranted.
引用
- Bajaj JS, O'Leary JG, Tandon P, et al. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. Aliment Pharmacol Ther. 2019. PMID: 31032966. doi:10.1111/apt.15265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。